Recent Finacing
Recent Raise
Shoreline Biosciences develops allogeneic iPSC-derived NK and macrophage cell therapies, engineering CARs and switchable CAR-NK engagers, advancing differentiation and reprogramming methods and CDMO/GMP manufacturing partnerships.
